APOC3 Antikörper

Produktnummer ABIN289326

Produktdetails anti-APOC3 Antikörper

Target: APOC3 (Apolipoprotein C-III (APOC3))

Reaktivität: Human

Wirt: Ziege

Klonalität: Polyklonal

Konjugat: Dieser APOC3 Antikörper ist unkonjugiert

Applikation: Western Blotting (WB), ELISA, Immunohistochemistry (IHC), Immunoprecipitation (IP)

Aufreinigung: Affinity chromatography purified

Immunogen: ApoC-III antibody was raised in goat using produced from apolipoprotein type C-III derived from human plasma as the immunogen.

Anwendungsinformationen

Applikationshinweise: ELISA: 1:5,000-1:10,000, IHC: 1:50-1:200, IP: 1:100, WB: 1:5,000-1:10,000
Optimal conditions should be determined by the investigator.

Beschränkungen: Nur für Forschungszwecke einsetzbar

Handhabung

Konzentration: Lot specific

Buffer: 0.125 M Na5 5 7, pH 8.0, with 0.075 NaCl, 0.005 EDTA, and 0.01 % NaN3.

Konservierungsmittel: Sodium azide

Vorsichtsmaßnahmen: This product contains Sodium Azide: a POISONOUS AND HAZARDOUS SUBSTANCE, which should be handled by trained staff only.

Handhabung: Avoid repeated freeze/thaw cycles.
Dilute only prior to immediate use.

Lagerung: 4 °C/-20 °C

Informationen zur Lagerung: Store at 4 °C for short term storage. Aliquot and store at -20 °C for long term storage.

Details zu APOC3

Target: APOC3 (Apolipoprotein C-III (APOC3))

Andere Bezeichnung: ApoC-III (APOC3 Produkte)

Synonyme: APOC3 antikoerper, APOCIII antikoerper, HALP2 antikoerper, Apoc antikoerper, ApoC-III antikoerper, apo-CIII antikoerper, Apo-CIII antikoerper, apolipoprotein C3 antikoerper, apolipoprotein C-III antikoerper, APOC3 antikoerper, Apoc3 antikoerper

Hintergrund: Apolipoprotein C-III is a very low density lipoprotein (VLDL). APOC3 inhibits lipoprotein lipase and hepatic lipase, it is thought to inhibit hepatic uptake of triglyceride-rich particles. The APOA1, APOC3 and APOA4 genes are closely linked in both rat and human genomes. The A-I and A-IV genes are transcribed from the same strand, while the A-1 and C-III genes are convergently transcribed. An increase in apoC-III levels induces the development of hypertriglyceridemia.

Pathways: Carbohydrate Homeostasis, Lipid Metabolism